Chasm Partners’ Post

Happy #groundhogday - What's new in #woundcare and #limbpreservation this week? RTI Surgical® is acquiring Cook Biotech – no news on the financial details of the transaction, but positions this as a strategy to increase their ability to develop both allograft and xenograft technologies at scale, as a CDMO it provides clear capabilities advancements. 📈 Earnings 📈 Essity – Full year 2023 of Health and Medical sales up 12.2% ($2.6B), growth in Q4 was ~6% and largely driven through a price/mix shift. Next Science – full year 2023 revenue of $22M, up almost 90% YoY. Attributed Q4 to strong wound care DME sales and growth in VA and LTC. 📢 News 📢 MolecuLight – awarded federal contract - The US Department of Veterans Affairs has awarded MolecuLight Corp. a Federal Supply Contract for its wound imaging devices that detect harmful bacteria, allowing clinicians to make real-time, bedside decisions for treatment. Celularity Inc. – Been busy in New Jersey!! Closed two financing rounds totaling $21M, the resignation of Robin L. Smith as a board member, guidance for full-year 2023 ~$22M, but wait – guidance for the full year 2024 of ~$50-$56M (that's some forecasted growth!!). Imbed Biosciences Inc. – awarded a woundcare agreement with Premier via a technology breakthrough designation for Pelashield. MiMedx – I recently covered a LOT of activity going on with them, but that ever-present fact that they are majority held by institutional investors… well, a law firm is investigating claims “on behalf of” investors, related to the warning letter. Likely to drive the price down, to buy more shares. Perceptive Solutions – Introduced the WoundZoom Pro demonstrating continued growth of shifts onto more accessible smartphone platforms and expansion of #ai Even "quiet" weeks - have consistent activity in this space. Now to see if #punxsutawney phil has any news for us.

Big news in Medtech! Merit Medical just made a bold $105M move, scooping up the EsophyX Z+ device from EndoGastric Solutions. This isn't just a win for Merit; it's a game-changer for those battling GERD. This smart addition is all about minimally invasive treatment, offering fresh hope and cutting-edge care without a single incision. With Merit Medical's focus on strategic growth, this deal isn't merely a purchase; it's a leap forward expanding their reach in gastrointestinal care. Thoughts on how this acquisition might change the playing field? Drop your take below! #Medtech #Innovation #HealthcareIndustry

🌐 Exciting News in MedTech! 🌐 🚀 Johnson & Johnson MedTech reaches a milestone with the completion of the acquisition of Laminar, Inc., a cutting-edge medical device company revolutionizing AFib treatment. 🏥 🤝 Joining forces with Biosense Webster, Johnson & Johnson MedTech is set to redefine cardiac arrhythmia treatment. The $400 million acquisition showcases a commitment to innovation in addressing non-valvular atrial fibrillation. 💙 🔬 Laminar's expertise in eliminating the left atrial appendage (LAA) brings a game-changing approach to patient care. 💡 Stay ahead in the ever-evolving landscape of healthcare by staying informed about this transformative acquisition. 💼 As the industry evolves, so does the potential for advancements. Learn how this strategic move positions Johnson & Johnson MedTech for future success. Explore the full details: https://lnkd.in/eTfFNC_R #MedTechInnovation #MedTech #HealthcareAdvancements #JohnsonAndJohnson

🔥 9 Hot MedTech Trends to Watch👇👇 An MLV Exclusive On-the-Record Q&A with Gert Bos, CSO at QServe Group Last week, I caught up with Gert Bos, PhD, FRAPS, between sessions at the Qserve Group's MedTech Conference in Amsterdam. After filling me in on the Kick-Off Session, I had many questions for him. To start with, I wanted to hear what he had to say about IVDR and the projected loss of IVDs from the market.  Q: Some have projected a potential loss of as many as 8,000 out of 27-28,000 IVDs. ✅ When asked about the current status, Gert Bos responded, “Well, in certain ways, for medical devices, we have so many competitors… But in IVDs, switching from one to the other is going to be much more difficult.” Q: Probing deeper, I asked if the projected loss of IVDs is still a genuine concern. ✅ According to Gert, “Talking about numbers, positive and negative, of course, nobody really knows if this losing 8,000 was realistic. That is one of the reasons why the Commission is now pushing for this survey.” Q: Can we expect less profitable IVD products to be phased out? ✅ The economic viability of keeping certain diagnostic products in the market has come under scrutiny. Gert highlighted this challenge by saying, “One is still the unknown for many of the manufacturers… a lot of products ultimately will be phased out, but nobody's telling because as soon as you say you will phase out, you'd lose your existing client base.” Q: How will this impact the Hospital Exemption and in-house Tests? ✅ In situations where there's a lack of available tests, hospitals may resort to their own solutions. Gert raised a pertinent question: “Is this really an improvement or is this just a pity due to the, you could say, the paperwork?” Beyond IVDR, he talked about a number of other hot #MedTechtrends he sees that I compiled into a helpful flipbook below. Please add your comments below, including HOT trends you would add to this! #IVDR #MDR #medicaldevices #regulation Sabina Hoekstra-van den Bosch, PharmD FRAPS, Sue Spencer, Bianca Lutters, Emily Piernick, Kristiane Schmidt, Chris Webb, Mario Minale

Belgian Firm Bedal Raises €10.2M for Catheter Securement Devices Exciting news in the medtech world! Diepenbeek-based Bedal International has successfully closed a €10.2M funding round to expand its innovative FlexGRIP catheter securement devices, enhancing patient care globally. This funding round, backed by prominent investors like White Fund, SFPIM, and notable US medtech investors, signifies strong confidence in Bedal's mission. Since its inception, Bedal has focused on developing securement solutions that prioritise patient comfort, addressing key challenges faced during intravenous catheter usage. The support from industry veterans and the recent appointment of Dr Steve Bierman as co-CEO promise a bright future for Bedal's growth and innovation. This new capital will accelerate Bedal's operational and commercial expansion, especially into the US market, further establishing FlexGRIP devices as a gold standard in catheter care. It's a thrilling chapter for Bedal, setting new benchmarks in medical devices with a profound impact on patients' lives. #Medtech #HealthcareInnovation #LifeSciences

Mainstay Medical, creator of a groundbreaking neurostimulation therapy for lower back pain, received a major vote of confidence as investors put together a $125 million equity financing deal. “A financing of this magnitude will allow us to accelerate our efforts to revolutionize the treatment of mechanical low back pain through ReActiv8 Restorative Neurostimulation, including by continuing our rapid commercial growth and building on our insurance coverage for ReActiv8,” said Jason Hannon, CEO of Mainstay Medical. The financing was co-led by Gilde Healthcare and Viking Global Investors, with the participation from Sofinnova Partners through its Crossover Strategy, Ally Bridge Group, Fountain Healthcare Partners, and PERCEPTIVE LIFE SCIENCES FUND L P. ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. ReActiv8 has received regulatory approval in several geographic areas, and is commercially available in the European Economic Area, Australia, the UK, and the US. Read more: https://hubs.ly/Q02mlkT_0 Cédric Moreau Claire Catherinet, PhD Medtronic Latham & Watkins Perceptive Advisors Matt Onaitis LifeSci Advisors, LLC Brian Ritchie FTI Consulting Jonathan Neilan #innovation #biotech #chroniclowbackpain #mainstaymedical #SofinnovaPartners #VentureCapital

5 companies to watch as medtech earnings wind down: Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.   Blog – Medical Billing - HHS proposes ‘powerful’ penalties for providers found information blocking - https://lnkd.in/g4tRrTa7   Health Exec -  97% of Healthcare Data Isn’t Used - https://lnkd.in/gFqpp9Js   Paul Young CPA CGA Senior Data and AI Thought Leader Data Strategy and Data Management Paul_Young_CGA@outlook.com #medtech# #healthcareinnovation #medicalequipment #healthcare #ESG #HIPAA #medicalbilling #efficiency #primarycare #privatecare #publiccare #hospitalcare #clinic

Qsight Alpha Expands Coverage with the Inclusion of LeMaitre Vascular The newest addition to Qsight Alpha’s Medical Device coverage is LeMaitre Vascular (LMAT). This has been a commonly requested company, and we are excited to be providing insights across the company’s portfolio of peripheral vascular disease products. Looking at the past ten quarters, Qsight has consistently outperformed market expectations and provided accurate insights to drive informed decision-making. During this time, the mean absolute percentage error in Qsight’s projections has been 1.79% With Qsight’s Alpha Hospital Purchasing Data, you will gain visibility into the medical devices and supplies purchased by over 3,500 U.S. facilities. We offer sales projections for 32 publicly traded companies in the MedTech space – all to inform your strategies with predictive insights. Book a demo today: https://lnkd.in/ekEzm4Uu #PredictiveAnalytics #MarketInsights #BusinessForecasting #QsightAlpha

This week in FemInnovation' Femtech Medical Consultant Certificate we are discussing #valuebasedcare and how it will change the way hospitals and clinics interact with #femtech products. Value based care is coming. #CMS plans to implement it by 2030 which will be here before we know it. The question is, how will #femtech companies respond? I'm loving the discussion with our first cohort about these topics and can't wait to see what they do when they finish. #Founders, what are you predictions about what will change with value based care in regards to #femtech? How about #clinicians? Bethany Corbin

#ICYMI: For INSIGHTEC, the path to clinical success has been anything but direct. The same is true for the company’s reimbursement strategy, having been one of the few product companies with innovative technology to make the successful leap from a cash pay to a global reimbursement model. Ultimately, despite the company’s global reach, Insightec’s success has been forged by the collaboration of reimbursement, regulatory, clinical, and commercial teams working together to overcome a decade of setbacks to create a future of opportunities. Read how INSIGHTEC is pioneering the use of MRI-guided focused ultrasound (MRgFUS) using its Exablate system as an incisionless therapy to treat conditions like Essential Tremor and Parkinson’s Disease: https://bit.ly/45b2JeJ #medtech #medicaldevices #reimbursement #regulatory #globalreimbursement #reimbursementstrategy